Abstract |
This is an ongoing study designed to evaluate the role of teicoplanin in the therapy of sternal wound infections following cardiac surgery caused by Gram-positive microorganisms. Intravenous teicoplanin therapy is begun in the hospital, but once the patients return home it is given as a single intramuscular dose of 400 mg/day. Only a limited number of patients have been recruited so far, but in these, the clinical success rate and the bacteriological elimination rate are 85%. Only one patient had to be withdrawn from the study due to intolerable side-effects. These preliminary results suggest that teicoplanin is suitable for the therapy of chest wound infections following cardiac surgery; a major part of the course can be administered at home in a single daily intramuscular injection. This novel therapy regimen is expected to reduce considerably the hospital costs involved in the therapy of sternal wound infections.
|
Authors | E Rubinstein |
Journal | The European journal of surgery. Supplement. : = Acta chirurgica. Supplement
(Eur J Surg Suppl)
Issue 567
Pg. 27-9
( 1992)
ISSN: 1102-416X [Print] England |
PMID | 1381638
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Glycopeptides
- Teicoplanin
|
Topics |
- Ambulatory Care
- Anti-Bacterial Agents
(administration & dosage, adverse effects, therapeutic use)
- Coronary Disease
(surgery)
- Glycopeptides
(administration & dosage, adverse effects, therapeutic use)
- Humans
- Mediastinitis
(drug therapy)
- Staphylococcal Infections
(drug therapy)
- Staphylococcus epidermidis
- Surgical Wound Infection
(drug therapy)
- Teicoplanin
|